title: A high risk of hepatitis C infection among Egyptian blood donors: the role of parenteral drug abuse.
abstract: To determine the prevalence and risk factors of hepatitis C virus (HCV) infection among Egyptian blood donors, 188 consecutive adult blood donors from four hospitals and one temporary donor center located in Cairo, Egypt were evaluated. Sera were tested for HCV antibodies (anti-HCV) using second-generation enzyme-linked immunosorbent assay (ELISA) test kits. Sera that were repeatedly reactive by ELISA were further verified by a second-generation recombinant immunoblot assay (RIBA). Antibodies to HCV were detected by RIBA in 26.6% of the blood donors, which is higher than the 10-19% prevalence of antibody found in other studies of Egyptian blood donors. A history of selling blood (odds ratio [OR] = 12.1) and the use of illicit parenteral drugs (OR = 2.5) were significantly associated with anti-HCV seropositivity after controlling for age and gender. These data indicate that the use of illicit drugs may be one reason for high levels of reported HCV infection among Egyptian blood donors. These findings also indicate that Egyptian blood donors should be screened for anti-HCV and individuals who have a history of drug abuse should be deferred from donating blood.
authors.affiliation: U.S. Naval Medical Research Unit No. 3, Cairo, Egypt.
authors.forename: S
authors.initials: S
authors.lastname: Bassily
authors.forename: K C
authors.initials: KC
authors.lastname: Hyams
authors.forename: R A
authors.initials: RA
authors.lastname: Fouad
authors.forename: M D
authors.initials: MD
authors.lastname: Samaan
authors.forename: R G
authors.initials: RG
authors.lastname: Hibbs
mesh_terms: D000293:Adolescent; D000328:Adult; D001782:Blood Donors / Q000706:statistics & numerical data; D004534:Egypt / Q000453:epidemiology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood; D006526:Hepatitis C / Q000453:epidemiology* / Q000209:etiology; D018937:Hepatitis C Antibodies; D006801:Humans; D015151:Immunoblotting; D008297:Male; D015995:Prevalence; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000150:complications*
chemical_list: D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies